Ionis Pharmaceuticals, Inc. (IONS) Stake Lowered by YorkBridge Wealth Partners LLC
YorkBridge Wealth Partners LLC lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 2.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,031 shares of the company’s stock after selling 48 shares during the period. YorkBridge Wealth Partners LLC’s holdings in Ionis Pharmaceuticals were worth $106,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. First Allied Advisory Services Inc. grew its holdings in shares of Ionis Pharmaceuticals by 9.9% during the 2nd quarter. First Allied Advisory Services Inc. now owns 5,463 shares of the company’s stock worth $279,000 after purchasing an additional 494 shares during the period. Balyasny Asset Management LLC acquired a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter worth about $702,000. Stifel Financial Corp increased its position in shares of Ionis Pharmaceuticals by 0.3% during the 2nd quarter. Stifel Financial Corp now owns 599,532 shares of the company’s stock worth $30,502,000 after purchasing an additional 1,684 shares during the last quarter. Numeric Investors LLC increased its position in shares of Ionis Pharmaceuticals by 14.1% during the 2nd quarter. Numeric Investors LLC now owns 8,100 shares of the company’s stock worth $412,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Ionis Pharmaceuticals by 15.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 196,812 shares of the company’s stock worth $10,014,000 after purchasing an additional 26,496 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.
In other news, Chairman Stanley T. Crooke sold 16,500 shares of Ionis Pharmaceuticals stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $52.45, for a total value of $865,425.00. Following the transaction, the chairman now directly owns 53,014 shares of the company’s stock, valued at approximately $2,780,584.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Patrick R. O’neil sold 1,000 shares of Ionis Pharmaceuticals stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $55.00, for a total value of $55,000.00. Following the completion of the transaction, the senior vice president now directly owns 10,633 shares in the company, valued at $584,815. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,500 shares of company stock valued at $2,122,175. 1.86% of the stock is owned by company insiders.
A number of research analysts have commented on IONS shares. Jefferies Group LLC reaffirmed an “underperform” rating and issued a $18.00 target price (up previously from $17.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, August 10th. Laidlaw reiterated a “buy” rating and set a $65.00 price target on shares of Ionis Pharmaceuticals in a research report on Monday, August 14th. BMO Capital Markets lifted their price target on shares of Ionis Pharmaceuticals from $67.00 to $69.00 and gave the company an “outperform” rating in a research report on Monday, August 14th. Sanford C. Bernstein started coverage on shares of Ionis Pharmaceuticals in a research note on Thursday, July 27th. They issued a “market perform” rating and a $57.00 price target on the stock. Finally, Stifel Nicolaus boosted their price target on shares of Ionis Pharmaceuticals from $42.00 to $50.00 and gave the company a “hold” rating in a research note on Wednesday, August 9th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company’s stock. Ionis Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $49.11.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) traded down 0.30% during trading on Monday, hitting $50.55. 100,404 shares of the company’s stock traded hands. Ionis Pharmaceuticals, Inc. has a 12-month low of $24.58 and a 12-month high of $60.01. The firm’s 50-day moving average price is $51.73 and its 200 day moving average price is $48.15. The stock has a market cap of $6.29 billion, a P/E ratio of 243.03 and a beta of 3.12.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.03). Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The firm had revenue of $104.15 million during the quarter, compared to analyst estimates of $93.29 million. During the same quarter in the previous year, the business posted ($0.47) EPS. Ionis Pharmaceuticals’s revenue was up 170.7% compared to the same quarter last year. Analysts anticipate that Ionis Pharmaceuticals, Inc. will post ($0.17) earnings per share for the current fiscal year.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.